GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » EV-to-FCF

Starpharma Holdings (Starpharma Holdings) EV-to-FCF : -4.14 (As of May. 02, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Starpharma Holdings's Enterprise Value is $18.14 Mil. Starpharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.38 Mil. Therefore, Starpharma Holdings's EV-to-FCF for today is -4.14.

The historical rank and industry rank for Starpharma Holdings's EV-to-FCF or its related term are showing as below:

SPHRY' s EV-to-FCF Range Over the Past 10 Years
Min: -77.97   Med: -20.88   Max: -1.71
Current: -4.08

During the past 13 years, the highest EV-to-FCF of Starpharma Holdings was -1.71. The lowest was -77.97. And the median was -20.88.

SPHRY's EV-to-FCF is ranked worse than
100% of 391 companies
in the Biotechnology industry
Industry Median: 4.48 vs SPHRY: -4.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-02), Starpharma Holdings's stock price is $0.90. Starpharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.149. Therefore, Starpharma Holdings's PE Ratio for today is At Loss.


Starpharma Holdings EV-to-FCF Historical Data

The historical data trend for Starpharma Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings EV-to-FCF Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.56 -35.84 -36.39 -18.61 -7.09

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -18.61 - -7.09 -

Competitive Comparison of Starpharma Holdings's EV-to-FCF

For the Biotechnology subindustry, Starpharma Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's EV-to-FCF falls into.



Starpharma Holdings EV-to-FCF Calculation

Starpharma Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=18.140/-4.381
=-4.14

Starpharma Holdings's current Enterprise Value is $18.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Starpharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Starpharma Holdings  (OTCPK:SPHRY) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Starpharma Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.90/-0.149
=At Loss

Starpharma Holdings's share price for today is $0.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Starpharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.149.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Starpharma Holdings EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (Starpharma Holdings) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (Starpharma Holdings) Headlines

From GuruFocus

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020

Starpharma creates slow release soluble DEP remdesivir nanoparticle

By Business Wire Business Wire 09-01-2020

Starpharma to present at OTCQX Virtual Investor Conference

By PRNewswire PRNewswire 04-11-2018

Starpharma Presentation Now Available for On-Demand Viewing

By PRNewswire PRNewswire 04-17-2018

Starpharma signs new DEP� agreement with MSD

By PRNewswire PRNewswire 08-10-2022

Starpharma's SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

By Business Wire Business Wire 09-14-2020